Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease.

Abstract

The neuropeptides neurokinin B, neurotensin, and anandamide, the endogenous ligands of NK3, NT1, and CB1 receptors respectively, are known to interact with brain dopaminergic transmission. This study evaluated the effects of these three antagonists of the NK3 (SR 142801), neurotensin (SR 48692), and cannabinoid (SR 141716) receptors on the severity of motor symptoms and levodopa-induced dyskinesias after administration of a single dose of levodopa in 24 patients with Parkinson disease. In this exploratory randomized, double-blind, placebo-controlled study, at the dose used, the drugs tested were well tolerated and could not improve parkinsonian motor disability.

• Authors: V Mesnage, J L Houeto, A M Bonnet, I Clavier, I Arnulf, F Cattelin, G Le Fur, P Damier, M L Welter, Y Agid
• Journal: Clinical neuropharmacology (Clin Neuropharmacol) 2004 May-Jun Vol. 27 Issue 3 Pg. 108-10 ISSN: 0362-5664 [Print] United States
• PMID: 15190231 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Antipsychotic Agents
• Cannabinoid Receptor Antagonists
• Piperidines
• Pyrazoles
• Quinolines
• Receptors, Neurotensin
• SR 48692
• Neurotensin
• Levodopa
• SR 142801
• Rimonabant

Topics

• Aged
• Antipsychotic Agents (pharmacology, therapeutic use)
• Cannabinoid Receptor Antagonists
• Double-Blind Method
• Dyskinesia, Drug-Induced (drug therapy, etiology)
• Female
• Humans
• Levodopa
• Male
• Middle Aged
• Movement Disorders (drug therapy, etiology)
• Neurotensin (antagonists & inhibitors)
• Parkinson Disease (complications, drug therapy)
• Piperidines (pharmacology, therapeutic use)
• Pyrazoles (pharmacology, therapeutic use)
• Quinolines (pharmacology, therapeutic use)
• Receptors, Neurotensin (antagonists & inhibitors)
• Rimonabant